edelfosine has been researched along with Leucocythaemia in 29 studies
edelfosine: RN given refers to parent cpd
edelfosine : A racemate comprising equimolar amounts of (R)- and (S)-edelfosine.
1-octadecyl-2-methylglycero-3-phosphocholine : A glycerophosphocholine that is glycero-3-phosphocholine substituted at positions 1 and 2 by octadecyl and methyl groups respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A survey of the in vitro activity of racemic 1-octadecyl-2-methoxy-glycero-3 phosphorylcholine on in vitro clonogenicity in soft agar and tritiated thymidine incorporation was conducted on bone marrow specimens from a series of patients with acute myelogenous leukemia (AML) and chronic myelocytic leukemia (CML) and hematologically normal individuals." | 3.67 | The effect of alkyl-lysophospholipids on tritiated thymidine incorporation and clonogenicity in vitro of normal and leukemic human cells. ( Long, RC; Somberg, LB; Vogler, WR; Whigham, EA; Winton, EF, 1984) |
| "440 and the ether-linked lipoidal amine CP-46,665 on tritiated thymidine uptake and trypan blue dye exclusion were tested in vitro in various freshly explanted cell samples from human nonneoplastic bone marrow and human leukemias." | 3.67 | Cytotoxic effects of ether lipids and derivatives in human nonneoplastic bone marrow cells and leukemic cells in vitro. ( Berdel, WE; Eibl, H; Fink, U; Fromm, M; Jehn, U; Rastetter, J; Reichert, A; Schick, HD; Ulm, K; Unger, C, 1987) |
| " Encapsulation of edelfosine (ET) in lipid nanoparticles (LNs) improves its oral bioavailability and decreases its toxicity." | 1.39 | Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines. ( Blanco-Príeto, MJ; Estella-Hermoso de Mendoza, A; Lasa-Saracíbar, B; Mollinedo, F; Odero, MD, 2013) |
| "Edelfosine treatment recruited Hsp90, c-Jun N-terminal kinase (JNK) and apoptotic molecules in lipid rafts, but not the JNK regulators apoptosis signal-regulating kinase 1 (ASK1) and Daxx, or the survival signaling molecules extracellular signal-regulated kinase (ERK) and Akt." | 1.35 | Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy. ( Gajate, C; González-Camacho, F; Mollinedo, F; Nieto-Miguel, T, 2008) |
| " All the mice given cells not treated with ALP succumbed to leukemia, whereas there was a dose-response increase in survival in those given ALP treated cells." | 1.28 | Purging leukemia remission marrows with alkyl-lysophospholipids, preclinical and clinical results. ( Berdel, WE; Glasser, L; Okamoto, S; Olson, AC; Vogler, WR, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (34.48) | 18.7374 |
| 1990's | 14 (48.28) | 18.2507 |
| 2000's | 4 (13.79) | 29.6817 |
| 2010's | 1 (3.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lasa-Saracíbar, B | 1 |
| Estella-Hermoso de Mendoza, A | 1 |
| Mollinedo, F | 5 |
| Odero, MD | 1 |
| Blanco-Príeto, MJ | 1 |
| Nieto-Miguel, T | 2 |
| Gajate, C | 4 |
| González-Camacho, F | 1 |
| Vogler, WR | 10 |
| Whigham, EA | 1 |
| Somberg, LB | 1 |
| Long, RC | 1 |
| Winton, EF | 3 |
| Heesbeen, EC | 1 |
| Rijksen, G | 1 |
| van Heugten, HG | 1 |
| Verdonck, LF | 1 |
| Berdel, WE | 12 |
| Berkovic, D | 1 |
| Berkovic, K | 1 |
| Fleer, EA | 2 |
| Eibl, H | 5 |
| Unger, C | 3 |
| Shoji, M | 4 |
| Fukuhara, T | 1 |
| Olson, AC | 5 |
| Hajdu, J | 2 |
| Raynor, R | 1 |
| Kuo, JF | 3 |
| Yamazaki, T | 1 |
| Sieber, F | 1 |
| Geller, RB | 1 |
| Brochstein, JA | 1 |
| Beveridge, RA | 1 |
| Dalton, WS | 1 |
| Miller, KB | 1 |
| Lazarus, HM | 1 |
| Santos-Beneit, AM | 1 |
| Macho, A | 1 |
| Lazaro, Md | 1 |
| Hernandez-De Rojas, A | 1 |
| Modolell, M | 1 |
| Muñoz, E | 1 |
| Min, WS | 1 |
| Park, HM | 1 |
| Han, CH | 1 |
| Park, JW | 1 |
| Kim, CC | 1 |
| Kim, DJ | 2 |
| Okamoto, S | 4 |
| Heffner, LT | 1 |
| Gordon, DS | 1 |
| Raynor, RL | 1 |
| Nomura, H | 1 |
| Glasser, L | 1 |
| Santos, GW | 1 |
| Colvin, OM | 1 |
| Lai, CS | 1 |
| Joseph, J | 1 |
| Shih, CC | 1 |
| Chabot, MC | 1 |
| Wykle, RL | 1 |
| Modest, EJ | 1 |
| Daniel, LW | 1 |
| Oishi, K | 1 |
| Zheng, B | 1 |
| White, JF | 1 |
| Fink, U | 3 |
| Rastetter, J | 3 |
| Danhauser, S | 1 |
| Schick, HD | 2 |
| Fromm, M | 2 |
| Reichert, A | 2 |
| Busch, R | 1 |
| Jehn, U | 1 |
| Ulm, K | 1 |
| Kötting, J | 1 |
| Bartsch, HH | 1 |
| Nagel, GA | 1 |
| Pfizenmaier, K | 1 |
| Roos, G | 1 |
2 reviews available for edelfosine and Leucocythaemia
| Article | Year |
|---|---|
Ether lipids in cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; Drug Evaluation; Drug Evaluation, Precl | 1990 |
Pharmacological purging of bone marrow with reference to autografting.
Topics: Adolescent; Adult; Animals; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Cell Separation; Ch | 1986 |
6 trials available for edelfosine and Leucocythaemia
| Article | Year |
|---|---|
Autologous bone marrow transplantation with alkyl-lysophospholipid-purged marrow.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 1993 |
A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow.
Topics: Adolescent; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Combi | 1996 |
Alkyl-lysophospholipid purging for autologous bone marrow transplantation in acute leukemia in second or subsequent remission after extramedullary relapse.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Bone Marrow Transplantation; Humans; | 1992 |
[Purging of leukemic cells using alkyllysophospholipid].
Topics: Antineoplastic Agents; Bone Marrow Purging; Humans; Leukemia; Phospholipid Ethers | 1992 |
Pharmacological purging of bone marrow with reference to autografting.
Topics: Adolescent; Adult; Animals; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Cell Separation; Ch | 1986 |
Clinical phase I pilot study of the alkyl lysophospholipid derivative ET-18-OCH3.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; | 1987 |
22 other studies available for edelfosine and Leucocythaemia
| Article | Year |
|---|---|
Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Chemistry, Physical; Drug Delivery Sys | 2013 |
Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Endoplasmic Reticulum; fas Receptor; HeLa Cel | 2006 |
Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy.
Topics: Antineoplastic Agents; Apoptosis; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; JNK Mitogen-Activa | 2008 |
The effect of alkyl-lysophospholipids on tritiated thymidine incorporation and clonogenicity in vitro of normal and leukemic human cells.
Topics: Bone Marrow Cells; Cell Line; Circadian Rhythm; Colony-Forming Units Assay; Humans; Leukemia; Lysoph | 1984 |
Influence of serum levels on leukemic cell destruction by the ether lipid ET-18-OCH3.
Topics: Antineoplastic Agents; Biological Factors; Bone Marrow Cells; Bone Marrow Purging; Cell Division; Ce | 1995 |
Inhibition of calcium-dependent protein kinase C by hexadecylphosphocholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine do not correlate with inhibition of proliferation of HL60 and K562 cell lines.
Topics: Antineoplastic Agents; Cell Division; Cell Membrane; Cytosol; Diglycerides; Dose-Response Relationsh | 1994 |
Different mechanisms of inhibition by alkyl-lysophospholipid and phorbol ester of granulocyte-macrophage colony-stimulating factor binding to human leukemic cell lines.
Topics: Antineoplastic Agents; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Iodine Radioisotope | 1994 |
Structure-function relationships of alkyl-lysophospholipid analogs in selective antitumor activity.
Topics: Antineoplastic Agents; Cell Division; Dose-Response Relationship, Drug; Hematopoietic Stem Cells; Hu | 1993 |
The alkyl-lysophospholipid, ET-18-OCH3 synergistically enhances the Merocyanine 540-mediated photoinactivation of leukemia cells: implications for the extracorporeal purging of autologous hematopoietic stem cells.
Topics: Animals; Antineoplastic Agents; Blood Component Removal; Cell Death; Combined Modality Therapy; Drug | 1997 |
Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; DNA Fragmentation; Enzyme | 2000 |
The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells.
Topics: Apoptosis; beta-Cyclodextrins; Cell Membrane; Centrifugation, Density Gradient; Cholesterol; Cyclode | 2001 |
Efficacy of purging clonogenic leukemia cells using ether lipid and hyperthermia for autologous bone marrow transplantation.
Topics: Antineoplastic Agents; Bone Marrow Purging; Bone Marrow Transplantation; Colony-Forming Units Assay; | 1992 |
Autologous bone marrow transplantation in acute leukemia with marrow purged with alkyl-lysophospholipid.
Topics: Adolescent; Adult; Antineoplastic Agents; Blood Platelets; Bone Marrow; Bone Marrow Cells; Bone Marr | 1992 |
Comparison of selective cytotoxicity of alkyl lysophospholipids.
Topics: Antineoplastic Agents; Cell Survival; Hematopoietic Stem Cells; Humans; Leukemia; Phospholipid Ether | 1991 |
Purging leukemia remission marrows with alkyl-lysophospholipids, preclinical and clinical results.
Topics: Acute Disease; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Bone Marrow Transplan | 1990 |
Molecular dynamics of antitumor ether-linked phospholipids in model membranes: a spin-label study.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents; DNA; Electron Spin Resonance Spectroscopy | 1989 |
Correlation of ether lipid content of human leukemia cell lines and their susceptibility to 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Humans; Leukemia; Membrane Lipids; Phosphol | 1989 |
Inhibition of Na,K-ATPase and sodium pump by anticancer ether lipids and protein kinase C inhibitors ET-18-OCH3 and BM 41.440.
Topics: Animals; Antineoplastic Agents; Cell Membrane; Cerebral Cortex; Erythrocytes; Humans; Leukemia; Lyso | 1988 |
Structure-cytotoxicity studies on alkyl lysophospholipids and some analogs in leukemic blasts of human origin in vitro.
Topics: Antineoplastic Agents; Cell Survival; Cytotoxins; Glyceryl Ethers; Humans; Leukemia; Lysophospholipi | 1987 |
Cytotoxic effects of ether lipids and derivatives in human nonneoplastic bone marrow cells and leukemic cells in vitro.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Survival; Cytotoxins; Humans; Leukemia; | 1987 |
Sensitivity of leukemia cell lines to cytotoxic alkyl-lysophospholipids in relation to O-alkyl cleavage enzyme activities.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line; Cell Survival; Dose-Response Relationship, | 1987 |
Sensitivity of human hematopoietic cell lines to an alkyl-lysophospholipid-derivative.
Topics: Cell Cycle; Cell Division; Cell Line; Cell Survival; DNA, Neoplasm; Hematopoietic Stem Cells; Humans | 1986 |